# NCT06248515 (NCT06248515)

> A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06248515
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Georgetown University
- Conditions: Thymoma; Thymic Carcinoma
- Interventions: Sacituzumab govitecan-hziy
- Enrollment: 18
- Primary outcome: Overall Response Rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06248515